Recent advances in the treatment of chronic hepatitis B

Bibliography

• Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;12(Suppl 1):S35-50
   Google Scholar
• Kao JH. Hepatitis B virus genotypes and hepatocellular carcinoma in Taiwan. Intervirology 2003;46:400-7
   PubMed Web of Science ®Google Scholar
• Lok AS. Chronic hepatitis B. N Engl J Med 2002;346:1682-3
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42
   PubMed Web of Science ®Google Scholar
• Liaw YF, Leung N, Kao JH, Asian–Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;2:263-83
   PubMed Web of Science ®Google Scholar
• Dianzani F. Biological basis for the clinical use of interferon. Gut 1993;34(Suppl):S74-6
   Google Scholar
• Wong DK, Cheung AM, O'Rourke K, Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-23
   PubMed Web of Science ®Google Scholar
• Moucari R, Korevaar A, Lada O, High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009;50:1084-92
   PubMed Web of Science ®Google Scholar
• Cooksley WG. Treatment with interferons (including pegylated interferons) in patients with hepatitis B. Semin Liver Dis 2004;24(Suppl 1):45-53
   PubMedGoogle Scholar
• Brunetto MR, Oliveri F, Colombatto P, Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon. J Hepatol 2003;39(Suppl 1):S164-7
   Google Scholar
• Hadziyannis SJ. Treatment paradigms on hepatitis B e antigen negative chronic hepatitis B patients. Expert Opin Investig Drugs 2007;16:777-86
   PubMed Web of Science ®Google Scholar
• Baker DE. Pegylated interferons. Rev Gastroenterolo Disord 2001;1:87-99
   PubMedGoogle Scholar
• Craxi A, Cooksley WG, Pegylated interferons for chronic hepatitis B. Antiviral Res. 2003;60:87-9
   Google Scholar
• Cooksley WG, Piratvisuth T, Lee SD, Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:298-305
   PubMed Web of Science ®Google Scholar
• Lau GK, Piratvisuth T, Luo KX, Peginterferon Alfa-2a, lamivudine and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95
   PubMed Web of Science ®Google Scholar
• Janssen HL, van Zonneveld M, Senturk H, Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-9
   PubMed Web of Science ®Google Scholar
• Piratvisuth T, Lau G, Chao YC, Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int 2008;2:102-10
   PubMed Web of Science ®Google Scholar
• Buster EH, Flink HJ, Cakaloglu Y, Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008;135:459-67
   PubMed Web of Science ®Google Scholar
• Marcellin P, Lau GK, Bonino F, Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-17
   PubMed Web of Science ®Google Scholar
• Marcellin P Piratvisuth T, Brunetto M, Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) with or without lamivudine: results of 4-year follow-up. J Hepatol 2008;48(Suppl 2):S46
   Google Scholar
• Feld JJ, Wong DK, Heathcote EJ. Endpoints of therapy in chronic hepatitis B. Hepatology 2009;49:96-102
   PubMed Web of Science ®Google Scholar
• Lai CL, Chien RN, Leung NW, A one-year trial of lamivudine for chronic hepatitis B.. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-8
   PubMed Web of Science ®Google Scholar
• Liaw YF, Leung NW, Chang TT, Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-80
   PubMed Web of Science ®Google Scholar
• Leung NW, Lai CL, Chang TT, Asia Hepatitis Lamivudine Study Group. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32
   PubMed Web of Science ®Google Scholar
• Chang TT, Lai CL, Chien RN, Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004;19:1276-82
   PubMed Web of Science ®Google Scholar
• Guan R, Lai CL, Liaw YF, Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B (abstr). J Gastroenterol Hepatol 2001;16:A60
   Google Scholar
• Dienstag JL, Goldin RD, Heathcote EJ, Histological outcome during longterm lamivudine therapy. Gastroenterology 2003;124:105-17
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Papatheodoridis GV, Dimou E, Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32:847-51
   PubMed Web of Science ®Google Scholar
• Lai CL, Shouval D, Lok AS, BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20
   PubMed Web of Science ®Google Scholar
• Lai CL, Gane E, Liaw YF, Globe Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-88
   PubMed Web of Science ®Google Scholar
• Yao GB, Zhu M, Cui ZY, A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. J Dig Dis 2009;10:131-7
   PubMed Web of Science ®Google Scholar
• Liaw YF. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir Chem Chemother 2001;12(Suppl 1):67-71
   PubMedGoogle Scholar
• Papatheodoridis GV, Dimou E, Dimakopoulos K, Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005;42:121-9
   PubMed Web of Science ®Google Scholar
• Zhang QQ, An X, Liu YH, Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol J 2011;8:72
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG, Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG, Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008;48:750-8
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos N, Heathcote EJ, Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-51
   PubMed Web of Science ®Google Scholar
• Bridges EG. Telbivudine preclinical safety studies suggest minimal risk of chronic toxicity, reproductive toxicity or carcinogenicity. J Hepatol 2006;44(Suppl 2):S147
   Google Scholar
• Liaw YF, Gane E, Leung N, GLOBE Study Group. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-95
   PubMed Web of Science ®Google Scholar
• Wursthorn K, Jung M, Riva A, Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010;52:1611-20
   PubMed Web of Science ®Google Scholar
• Locarnini S. Primary resistance, multidrug resistance and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int 2008;2:147-51
   PubMed Web of Science ®Google Scholar
• Lai CL, Rosmawati M, Lao J, Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002;123:1831-8
   PubMed Web of Science ®Google Scholar
• Baldick CJ, Tenney DJ, Mazzucco CE, Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology 2008;47:1473-82
   PubMed Web of Science ®Google Scholar
• Chang TT, Gish RG, de Man R, BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10
   PubMed Web of Science ®Google Scholar
• Chang TT, Lai CL, Kew Yoon S, Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422-30
   PubMed Web of Science ®Google Scholar
• Gish RG, Lok AS, Chang TT, Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133:1437-44
   PubMed Web of Science ®Google Scholar
• Gish RG, Chang TT, Lai CL, Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat 2010;17:16-22
   PubMed Web of Science ®Google Scholar
• Chang TT, Liaw YF, Wu SS, Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-93
   PubMed Web of Science ®Google Scholar
• Woo G, Tomlinson G, Nishikawa Y, Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010;139:1218-29
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Rose RE, Baldick CJ, Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-14
   PubMed Web of Science ®Google Scholar
• Marcellin P, Heathcote EJ, Buti M, Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-55
   PubMed Web of Science ®Google Scholar
• Marcellin P, Buti M, Krastev Z, Continued efficacy and safety through 4 years of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-negative patients with chronic hepatitis B (Study 102): preliminary analysis. Hepatology 2010;52(Suppl):555A
   Google Scholar
• Heathcote E, Gane EJ, deMan RA, Long term (4 Year) efficacy and safety of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-positive patients (HBeAg+) with chronic hepatitis B (Study 103): preliminary analysis. Hepatology 2010;52(Suppl):556A
   Google Scholar
• Herlitz LC, Mohan S, Stokes MB, Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological and mitochondrial abnormalities. Kidney Int 2010;78:1171-7
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Doo E, Liang TJ, Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007;45:1056-75
   PubMed Web of Science ®Google Scholar
• Schalm SW, Heathcote J, Cianciara J, Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-8
   PubMed Web of Science ®Google Scholar
• Sanantonio T, Niro GA, Sinisi E, Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B: a controlled pilot study. J Hepatol 2002;36:799-804
   PubMed Web of Science ®Google Scholar
• Piccolo P, Lenci I, Demelia L, A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther 2009;14:1165-74
   PubMed Web of Science ®Google Scholar
• Wang LC, Chen EQ, Cao J, De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naive HBeAg-negative chronic hepatitis B patients. Hepatol Int 2011; Epub ahead of print
   Web of Science ®Google Scholar
• Liaw YF, Sheen IS, Lee CM, Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62-72
   PubMed Web of Science ®Google Scholar
• Lok AS, Zoulim F, Locarnini S, Hepatitis B Virus Drug Resistance Working Group. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007;46:254-65
   PubMed Web of Science ®Google Scholar
• Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 2009;49(5 Suppl):S174-84
   PubMed Web of Science ®Google Scholar
• Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 2011;8:275-84
   PubMed Web of Science ®Google Scholar
• Sherman M, Yurdaydin C, Sollano J, AI463026 BEHoLD Study Group. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-49
   PubMed Web of Science ®Google Scholar
• Sherman M, Yurdaydin C, Simsek H, AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virological, biochemical and serology outcomes through 96 weeks. Hepatology 2008;48:99-108
   PubMed Web of Science ®Google Scholar
• Reijnders JG, Deterding K, Petersen J, VIRGIL Surveillance Study Group. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010;52:493-500
   PubMed Web of Science ®Google Scholar
• van Bommel F, de Man RA, Wedemeyer H, Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010;51:73-80
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic Hepatitis B. N Engl J Med 2005;352:2673-81
   PubMed Web of Science ®Google Scholar
• Villet S, Pichoud C, Billioud G, Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008;48:747-55
   PubMed Web of Science ®Google Scholar
• Heo NY, Lim YS, Lee HC, Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol 2010;53:449-54
   PubMed Web of Science ®Google Scholar
• Brunelle MN, Jacquard AC, Pichoud C, Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005;41:1391-8
   PubMed Web of Science ®Google Scholar
• Leemans WF, Niesters HG, van der Eijk AA, Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir. Eur J Gastroenterol Hepatol 2008;20:773-7
   PubMed Web of Science ®Google Scholar
• Kobashi H, Fujioka S, Kawaguchi M, Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B. Hepatol Int 2009;3:403-10
   PubMed Web of Science ®Google Scholar
• Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virological response in hepatitis B and C. J Hepatol 2008;49:634-51
   PubMed Web of Science ®Google Scholar
• Iloeje UH, Yang HI, Su J, Predicting liver cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-86
   PubMed Web of Science ®Google Scholar
• Chen CJ, Yang HI, Su J, Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73
   PubMed Web of Science ®Google Scholar
• Lin CL, Kao JH. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci 2008;15:137-45
   PubMedGoogle Scholar
• Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003;37:1309-19
   PubMed Web of Science ®Google Scholar
• Perrillo RP, Lai CL, Liaw YF, Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186-94
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Gane E, Liaw YF, Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009;51:11-20
   PubMed Web of Science ®Google Scholar
• Bonino F, Marcellin P, Lau GK, Peginterferon alfa-2a HBeAg-negative chronic hepatitis B study group. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007;56:699-705
   PubMed Web of Science ®Google Scholar
• Lim SG, Marcellin P, Tassopoulos N, Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B. Aliment Pharmacol Ther 2007;26:1419-28
   PubMed Web of Science ®Google Scholar
• Tseng TC, Yu ML, Liu CJ, Impact of host and viral factors on HBeAg-positive chronic hepatitis B patients receiving peginterferon alfa-2a therapy. Antivir Ther 2011 (In press)
   Google Scholar
• Nguyen T, Desmond P, Locarnini S. The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int 2009;3:S5-15
   PubMed Web of Science ®Google Scholar
• Thompson AJV, Nguyen T, Iser D, Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010;51:1933-44
   PubMed Web of Science ®Google Scholar
• Jaroszewicz J, Serrano BC, Wursthorn K, Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010;52:514-22
   PubMed Web of Science ®Google Scholar
• Su TH, Hsu CS, Chen CL, Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. Antivir Ther 2010;15:1133-9
   PubMed Web of Science ®Google Scholar
• Sonneveld MJ, Rijckborst V, Boucher CA, Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010;52:1251-7
   PubMed Web of Science ®Google Scholar
• Rijckborst V, Hansen BE, Cakaloglu Y, Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010;52:454-61
   PubMed Web of Science ®Google Scholar
• Lee JM, Ahn SH, Kim HS, Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology 2011;53:1486-93
   PubMed Web of Science ®Google Scholar
• Fried MW, Piratvisuth T, Lau GK, HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008;47:428-34
   PubMed Web of Science ®Google Scholar
• Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol 2011;26(Suppl 1):123-30
   PubMed Web of Science ®Google Scholar
• Hou J, Schilling R, Janssen HLA. Molecular characteristics of hepatitis B virus genotype A confer a higher response to interferon treatment. J Hepatol 2001;34(Suppl 1):15
   Google Scholar
• Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002;36:1425-30
   PubMed Web of Science ®Google Scholar
• Erhardt A, Blondin D, Hauck K, Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005;54:1009-13
   PubMed Web of Science ®Google Scholar
• Marcellin P, Bonino F, Lau GK, Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009;136:2169-79
   PubMed Web of Science ®Google Scholar
• Wiegand J, Hasenclever D, Tillmann HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther 2008;13:211-20
   PubMed Web of Science ®Google Scholar
• Buster EH, Hansen BE, Lau GK, Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009;137:2002-9
   PubMed Web of Science ®Google Scholar
• Chien RN, Yeh CT, Tsai SL, Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003;38:1267-73
   PubMed Web of Science ®Google Scholar
• Yuen MF, Wong DK, Sablon E, Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir Ther 2003;8:531-4
   PubMed Web of Science ®Google Scholar
• Chan HL, Wong ML, Hui AY, Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. World J Gastroenterol 2003;9:2695-7
   PubMed Web of Science ®Google Scholar
• Buti M, Cotrina M, Valdes A, Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine? J Hepatol 2002;36:445-6
   PubMed Web of Science ®Google Scholar
• Westland C, Delaney W IV, Yang H, Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology 2003;125:107-16
   PubMed Web of Science ®Google Scholar
• . Hou J, Yin YK, Xu D, Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B. Results at 1 year of a randomized, double-blind trial. Hepatology 2008;47:447-54
   PubMed Web of Science ®Google Scholar
• Hsieh TH, Tseng TC, Liu CJ, Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C. Antivir Ther 2009;14:1157-63
   PubMed Web of Science ®Google Scholar
• Tseng TC, Liu CJ, Kao JH. Implications of hepatitis B virus genomic variations on treatment outcomes. Curr Pharmacogenomics Personalized Med 2010;8:280-8
   Google Scholar
• Tseng TC, Liu CJ, Wang CC, Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels. Antivir Ther 2009;14:203-10
   PubMed Web of Science ®Google Scholar
• Yuen MF, Fong DY, Wong DK, Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007;46:1695-703
   PubMed Web of Science ®Google Scholar
• Shin JW, Park NH, Jung SW, Clinical usefulness of sequential hepatitis B virus DNA measurement (the roadmap concept) during adefovir treatment in lamivudine-resistant patients. Antivir Ther 2009;14:181-6
   PubMed Web of Science ®Google Scholar
• Lee JM, Park JY, Kim do Y, Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Antivir Ther 2010;15:235-41
   PubMed Web of Science ®Google Scholar
• Leung N, Peng CY, Hann HW, Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009;49:72-9
   PubMed Web of Science ®Google Scholar
• Nguyen MH, Keeffe EB. Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. J Viral Hepat 2009;16:149-55
   PubMed Web of Science ®Google Scholar
• Keeffe EB, Zeuzem S, Koff RS, Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5:890-7
   PubMed Web of Science ®Google Scholar
• Brunetto MR, Moriconi F, Bonino F, Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009;49:1141-50
   PubMed Web of Science ®Google Scholar
• Moucari R, Mackiewicz V, Lada O, Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151-7
   PubMed Web of Science ®Google Scholar
• Moucari R, Lada O, Marcellin P. Chronic hepatitis B: back to the future with HBsAg. Expert Rev Anti Infect Ther 2009;7:633-6
   PubMed Web of Science ®Google Scholar
• Moucari R, Marcellin P. Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B. Liver Int 2011;31(Suppl 1):122-8
   PubMedGoogle Scholar
• Reijnders JG, Rijckborst V, Sonneveld MJ, Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2011;54:449-54
   PubMed Web of Science ®Google Scholar
• Frodsham AJ. Host genetics and the outcome of hepatitis B viral infection. Transpl Immunol 2005;14:183-6
   PubMed Web of Science ®Google Scholar
• Kamatani Y, Wattanapokayakit S, Ochi H, A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009;41:591-5
   PubMed Web of Science ®Google Scholar
• Thomas DL, Thio CL, Martin MP, Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801
   PubMed Web of Science ®Google Scholar
• Ge D, Fellay J, Thompson AJ, Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401
   PubMed Web of Science ®Google Scholar
• Huang HH, Shih WL, Li YH, Hepatitis B viraemia: its heritability and association with common genetic variation in the interferon gamma signalling pathway. Gut 2011;60:99-107
   PubMed Web of Science ®Google Scholar
• Chan HL, Tse AM, Zhang MD, Genetic polymorphisms of interleukin-1-beta in association with sustained response to anti-viral treatment in chronic hepatitis B in Chinese. Aliment Pharmacol Ther 2006;23:1703-11
   PubMed Web of Science ®Google Scholar
• King JK, Yeh SH, Lin MW, Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: a pilot study. Hepatology 2002;36:1416-24
   PubMed Web of Science ®Google Scholar
• Wu X, Zhu X, Zhu S, A pharmacogenetic study of polymorphisms in interferon pathway genes and response to interferon-alpha treatment in chronic hepatitis B patients. Antiviral Res 2009;83:252-6
   PubMed Web of Science ®Google Scholar
• Kao JH. Appropriate use of interferon for treatment of chronic hepatitis B. Hepatol Res 2007;37:S47-54
   Web of Science ®Google Scholar
• Rijckborst V, Sonneveld MJ, Janssen HL. Review article: chronic hepatitis B – anti-viral or immunomodulatory therapy? Aliment Pharmacol Ther 2011;33:501-13
   PubMed Web of Science ®Google Scholar
• Shamliyan TA, Johnson JR, Macdonald R, Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection. J Gen Intern Med 2011;26:326-39
   PubMed Web of Science ®Google Scholar